{"url_path":"/sec/mplt/8-k/2026-05-14/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1770069/0001193125-26-224067-index.html","accession_number":"0001193125-26-224067","cik":"0001770069","ticker":"MPLT","issuer_name":"MapLight Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1770069/0001193125-26-224067-index.html","primary_entity_key":"0001770069","primary_entity_name":"MapLight Therapeutics, Inc."},"word_count":84,"has_tables":true,"body_markdown":"## Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\n\nNumber\n\nDescription\n\n99.1\n\n \n\n[Press Release, dated May 14, 2026](mplt-ex99_1.htm)\n\n99.2\n\n \n\n[Corporate Presentation, dated May 14, 2026](mplt-ex99_2.htm)\n\n104\n\n \n\nCover Page Interactive Data File (formatted as inline XBRL).\n\n##  \n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nMapLight Therapeutics, Inc.\n\n \n\n \n\n \n\n \n\nDate:\n\nMay 14, 2026\n\nBy:\n\n/s/ Christopher Kroeger\n\n \n\n \n\n \n\nChristopher A. Kroeger, M.D.\nChief Executive Officer"}